دورية أكاديمية
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
| العنوان: | Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry |
|---|---|
| المؤلفون: | Cotes Sanchís, Almudena, Gallego, Javier, Hernandez, Raquel, Arrazubi, Virginia, Custodio, Ana, Cano, Juana María, Aguado, Gemma, Macias, Ismael, Lopez, Carlos, López, Flora, Visa, Laura, Garrido, Marcelo, Martínez Lago, Nieves, Fernández Montes, Ana, Limón, María Luisa, Azkarate, Aitor, Pimentel, Paola, Reguera, Pablo, Ramchandani, Avinash, Cacho, Juan Diego, Martín Carnicero, Alfonso, Granja, Mónica, Martín Richard, Marta, Hernández Pérez, Carolina, Hurtado, Alicia, Serra, Òlbia, Buxo, Elvira, Vidal Tocino, Rosario, Jimenez Fonseca, Paula, Carmona Bayonas, Alberto |
| المصدر: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
| بيانات النشر: | Public Library of Science (PLoS) |
| سنة النشر: | 2020 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Càncer d'estómac, Qualitat de vida, Metàstasi, Stomach cancer, Quality of life, Metastasis |
| الوصف: | Background: Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. Materials and methods: The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). Results: 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's tau = 0.613), lower in those subjects who received second-line (Kendall's tau = 0.539), especially with ramucirumab+CT (Kendall's tau = 0.413). Conclusion: This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 16 p.; application/pdf |
| اللغة: | English |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0235848Test; PLoS One, 2020, vol. 15, num. 7, p. e0235848; https://doi.org/10.1371/journal.pone.0235848Test; http://hdl.handle.net/2445/173470Test |
| الإتاحة: | https://doi.org/10.1371/journal.pone.0235848Test http://hdl.handle.net/2445/173470Test |
| حقوق: | cc by (c) Cotes Sanchís et al., 2020 ; http://creativecommons.org/licenses/by/3.0/esTest/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.168E9922 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |